Loading organizations...
§ Private Profile · One Highwood Drive, Suite 300. Tewksbury, MA 01876. USA
Medical device developer developing transcatheter devices to treat HFpEF/HFmrEF heart failure, focused on the Corvia Atrial Shunt.
Founded in 2009 by David Celermajer, Corvia Medical is a Tewksbury, Massachusetts-based medical device company developing transcatheter cardiovascular devices to treat heart failure. Led by CEO George Fazio, the privately held enterprise specifically targets patients diagnosed with heart failure with preserved and mildly reduced ejection fraction through its primary product, the minimally invasive Corvia Atrial Shunt. This implantable device is currently undergoing the RESPONDER-HF clinical trial at more than 65 medical institutions distributed across three continents to secure final FDA regulatory approval. Operating with fewer than 25 employees, the organization generates approximately $23.4 million in annual revenue and has accumulated $113.1 million in total venture funding to date. A recent $55 million financing round to complete this trial was backed by institutional venture capital investors including Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures.
Corvia Medical has raised $163.0M across 5 funding rounds.
Corvia Medical has raised $163.0M in total across 5 funding rounds.
Corvia Medical has raised $163.0M across 5 funding rounds. Most recently, it raised $55.0M Series U in June 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2025 | $55M Series U | — | General Catalyst, Greylock, LGF, Sequoia Capital, Third Rock Ventures, John Collison, SAM Altman, Scott Belsky, Vivek Patel | Announced |
| Jun 13, 2022 | $54M Venture Round | — | Accelmed, Edwards Lifesciences, General Catalyst, Lumira Ventures, Third Rock Ventures | Announced |
| Jun 1, 2014 | $34M Series D | Accelmed | General Catalyst, Greylock, LGF, Sequoia Capital, Third Rock Ventures, John Collison, SAM Altman, Scott Belsky, Vivek Patel, Lumira Ventures | Announced |
| Mar 20, 2013 | $9M Venture Round | — | Hemant Taneja, Gerry Brunk, Mark Levin | Announced |
| Feb 1, 2013 | $11M Series C | — | General Catalyst, Greylock, LGF, Sequoia Capital, Third Rock Ventures, John Collison, SAM Altman, Scott Belsky, Vivek Patel | Announced |
Corvia Medical has raised $163.0M in total across 5 funding rounds.
Corvia Medical's investors include General Catalyst, Greylock, LGF, Sequoia Capital, Third Rock Ventures, John Collison, Sam Altman, Scott Belsky, Vivek Patel, Accelmed, Edwards Lifesciences, Lumira Ventures.
Corvia Medical is a medical technology company developing the Corvia Atrial Shunt, a minimally invasive, catheter-based cardiac implant for patients with symptomatic heart failure (HF), particularly heart failure with preserved ejection fraction (HFpEF) where ejection fraction is ≥40%.[1][2][3] The device creates a passage between the left and right atria to reduce elevated left atrial pressure (LAP)—the primary cause of HF symptoms like breathlessness during exertion—lowering HF events, hospitalizations, and improving quality of life for over 26 million people worldwide affected by HF, with more than half having HFpEF.[2][3][4] It serves HF patients underserved by existing therapies, offering dynamic LAP decompression independent of medication compliance or daily monitoring, and has been implanted in 675+ patients across 100+ hospitals in 18 countries, with some patients over 10 years post-implant.[3][6] Recent momentum includes CE Mark certification under EU MDR standards in December 2024 and a $55 million funding round in 2025 to complete the RESPONDER-HF confirmatory trial and pursue FDA approval, building on FDA Breakthrough Device designation from 2019.[2][5]
Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical emerged to address the massive unmet need in HFpEF treatment, where over 50% of HF patients with EF >40% lack effective options despite guideline-directed medical therapy.[2][4][5] The company was established by leaders passionate about transcatheter cardiovascular devices to revolutionize HF care, with early development leading to CE Mark approval for the Corvia Atrial Shunt in 2016 as the first commercially available interatrial shunt for HF in Europe.[4] Pivotal moments include extensive clinical validation through trials like REDUCE LAP-HF II (showing long-term favorable effects on heart structure) and the ongoing RESPONDER-HF study, alongside implantation milestones reaching 675+ patients globally.[3][6] Leadership, including CEO George Fazio and Board Chair Paul LaViolette, has driven this evolution, supported by executives like VP Kate Stohlman with deep expertise in interventional cardiology devices.[5][7]
Corvia rides the wave of transcatheter structural heart interventions, expanding beyond valves (e.g., TAVR, MitraClip) to pressure-modulation therapies for HFpEF—the largest unmet cardiovascular need, affecting >13 million globally with no approved devices until now.[2][4][5] Timing aligns with aging populations driving HF prevalence (26M+ cases), demand for personalized medicine, and post-pandemic focus on reducing hospitalizations via outpatient procedures.[1][3] Market forces favor it: proven symptom relief independent of meds addresses non-compliance (nearly 50% of patients), while EU availability and U.S. trial data position Corvia to influence standards, potentially enabling millions to "reclaim their lives" and reshaping medtech ecosystems around LAP-focused innovations.[2][4][5]
Corvia is primed for U.S. commercialization post-$55M funding and RESPONDER-HF completion, targeting FDA approval to tap the massive HFpEF market amid rising transcatheter adoption.[5] Trends like AI-guided personalization, expanded structural heart procedures, and value-based care (emphasizing HF event reduction) will accelerate uptake, with global expansion leveraging 18-country experience.[3][6] Its influence could evolve from pioneer to category leader, fundamentally altering HF treatment like TAVR did for aortic stenosis—transforming lives for symptomatic patients long underserved, directly fulfilling its mission to revolutionize heart failure care.[2][5]